肺炎克雷伯菌
粘菌素
头孢他啶/阿维巴坦
磷霉素
阿米卡星
肉汤微量稀释
微生物学
头孢他啶
阿维巴坦
琼脂稀释
碳青霉烯
庆大霉素
医学
最小抑制浓度
抗生素
生物
大肠杆菌
细菌
铜绿假单胞菌
基因
生物化学
遗传学
作者
Nazmiye Ülkü Tüzemen,Uğur Önal,Osman Merdan,Bekir Akça,Beyza Ener,Cüneyt Özakın,Halis Akalın
标识
DOI:10.1038/s41598-024-67347-5
摘要
Carbapenem-resistant Klebsiella pneumoniae (CPKP) infections seriously threaten global public health. The main objective of this study was to assess the in-vitro synergistic activity of ceftazidime-avibactam (CZA) in combination with colistin (COL), amikacin (AK), gentamicin (GEN), and fosfomycin (FOS) against CPKP isolates. The secondary goal was to determine the antibiotic susceptibility performance of BD Phoenix. OXA-48 (49.1%) was the predominant carbapenemase, followed by KPC (29.1%). We used the broth microdilution (BMD) method to determine the minimum inhibitory concentrations (MICs) of CZA, COL, AK, and GEN. Meanwhile, the MICs of FOS were determined by the agar dilution (AD) method. To examine the antibacterial activity of CZA, we conducted a checkerboard assay (CBA) with COL, AK, GEN, and FOS against CRKP isolates. We randomly selected three strains and performed synergy testing via time-kill assay (TKA). CRKP isolates were 89.1% susceptible to CZA, 16.4% to COL, 21.8% to GEN, and 29.1% to AK using BMD, 47.3% to FOS by AD. The most synergistic effects were observed in the combination of CZA-COL (78.2%) and CZA-FOS (63.6%). Given the limited therapeutic options for treating severe CRKP infections, combining CZA with COL and FOS may enhance in-vitro activity against clinical CRKP isolates.
科研通智能强力驱动
Strongly Powered by AbleSci AI